Belite Bio, Inc
BLTE
Updated: 24/09/2026, 12:08:48
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
No summaries found.
- Share price
- $168.67
- Market cap
- $6.76B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Yu-Hsin Lin
- Employees
- 41
- IPO date
- 29/04/2022
- Beta
- -1.235
- Last dividend
- $0.00
- Day range
- $166.60 – $175.50
- 52-week range
- $68.21 – $200.00
- 1-day performance
- -3.81%
- 1-year performance
- 147.28%
- Current drawdown (1Y)
- -15.67%
- CIK
- 0001889109
- CUSIP
- 07782B104
- ISIN
- US07782B1044
- Created
- 07/12/2025, 03:02:13
- Last update
- 24/09/2026, 12:08:48
Track Belite Bio, Inc with an AI analyst
See which prediction-market events move BLTE, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
GlobeNewsWire • STOCK • 12/06/2026, 23:30:00
Belite Bio, Inc (BLTE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 08/06/2026, 21:28:30
Belite Bio, Inc (BLTE) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 20/05/2026, 21:20:58
Belite Bio Q1 Earnings Call Highlights
MarketBeat • STOCK • 20/05/2026, 20:07:07
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
GlobeNewsWire • STOCK • 20/05/2026, 08:00:00
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
GlobeNewsWire • STOCK • 18/05/2026, 18:00:00
Belite Bio, Inc (BLTE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 14/05/2026, 00:50:45
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results
GlobeNewsWire • STOCK • 13/05/2026, 18:00:00
Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor Conference Transcript
Seeking Alpha • STOCK • 28/04/2026, 13:31:48
Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th
GlobeNewsWire • STOCK • 22/04/2026, 10:35:00
Belite Bio, Inc (BLTE) Q4 2025 Earnings Call Transcript
Seeking Alpha • STOCK • 03/03/2026, 07:12:12
Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
GlobeNewsWire • STOCK • 02/03/2026, 07:00:00